Symbiotec Pharmalab will host an earnings conference call to discuss its financial performance for the quarter ended June 30, 2026 (Q1FY27). The event is scheduled for Tuesday, September 22, 2026, at 10:00 am IST.

The call is being hosted by JM Financial Institutional Securities Limited. It will be conducted via virtual audio conference.

Call Details

The management team participating in the discussion includes:

• Anil Satwani (Promoter & CMD)
• Raghavender Ramachandran (Chief Financial Officer)

Investors and analysts can join the call using the universal dial-in numbers +91 22 6280 1366 or +91 22 7115 8267. International toll-free numbers are available for the USA, UK, Singapore, and Hong Kong.

Participants are advised to dial in 10 minutes prior to the scheduled start time. The company has stated that no unpublished price-sensitive information will be shared during the call.

Regulatory Compliance

The intimation is issued pursuant to Regulation 30 read with Para A of Schedule III and Regulation 46(2) of the SEBI Listing Regulations, 2015. The schedule is subject to change due to exigencies.

Further information is available on the company’s investor relations website at investor.symbiotec.com.

Promoters of Symbiotec Pharmalab have re-created an encumbrance over 66,92,638 equity shares, representing 10.45% of the company’s total share capital. The pledge was registered in favour of Beacon Trusteeship Limited on September 11, 2026.

The disclosure was made pursuant to Regulation 31(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Beacon Trusteeship Limited acted in its capacity as the debenture trustee for Satwani Holdings (India) Private Limited (SHIPL).

Pledge Re-Creation Context

The company stated that the pledge was originally created on December 10, 2025, by certain members of the promoter group pursuant to a Target Pledge Agreement. It was temporarily released solely to enable the creation of applicable lock-ins on pre-issue shareholding in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Upon completion of the lock-in process and the Initial Public Offer, the pledge has been re-created over the relevant equity shares. The company described this as an administrative process with effectively no change in the pledged holding.

Encumbrance Details

The encumbrance serves as security for non-convertible debentures issued by SHIPL. A debenture trust deed dated December 10, 2025, as amended on December 18, 2025, governs the transaction. Under the terms, Mr. Anil Satwani and Mrs. Kashish Satwani created a charge over 100% of their partnership interest in Satwani Holdings LLP.

Satwani Holdings LLP currently holds 98,19,885 equity shares of Symbiotec Pharmalab, constituting 15.28% of the share capital on a fully diluted basis.

Promoter Pledge Breakdown

Members of the promoter group created pledges over specific shareholdings between September 8 and September 10, 2026. The total pledged shares amount to 66,92,638.

Covenant Conditions

The debenture trust deed includes a covenant regarding promoter ownership levels. If the promoter group ceases to own at least 26% of the equity share capital or voting rights in the target group, free from encumbrance, the associated debt must be repaid.

The promoter group comprises Mr. Anil Satwani, Mrs. Kashish Satwani, Mr. Sushil Satwani, Satwani Holdings LLP, and three family trusts: Krishna Anil Satwani Family Trust, Arjun Anil Satwani Family Trust, and Kashish and Anil Satwani Family Trust.